A Phase 1 interventional study of Dexmethylphenidate in Healthy Volunteers in Fed and Fasted State, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Cingulate Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Fasting with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Fasting · United States.
Among the 95 studies in Fasting with a site in United States, this one is the 61st largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2024, is one of 19 in phase 1, and was the 87th registered.
392 studies on the registry are indexed under Fasting; 63 are open to participants now.
Browse Fasting studies →19 of the 95 studies in Fasting with a site in United States are open now. Recruiting first, the newest first:
University of California, San Diego · Sites in United States
Ages 18–75
University of Illinois at Chicago · Sites in United States
Ages 25–99 · Women only
Ayal A. Aizer, MD · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 5 · Phase 3 1 · Phase 4 1
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 45 across 311 interventional studies indexed under Fasting.
Median enrollment 39 across the 85 interventional studies, 42 across the 10 observational. Of the 68 that completed or were terminated, 18 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 95 have an industry lead sponsor. The 10 most frequent:
Cingulate Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Cingulate Therapeutics has 2 studies filed under Fasting — fewer than ten, so there is no comparison to draw.
8 of the studies in Fasting with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387445University of Illinois at ChicagoFeasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer. | 2026-12-31 |
| NCT04893226Julie PendergastCircadian Rhythms in Postmenopausal Women | 2027-01-31 |
| NCT06884059University of California, San DiegoTime Restricted Eating in Patients With Microalbuminuria | 2027-02 |
| NCT05545306National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure | 2027-02-02 |
| NCT03523377Memorial Sloan Kettering Cancer CenterOvernight Fasting After Completion of Therapy: The OnFACT Study | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Fasting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the effect of food on the rate and extent of absorption and the overall bioavailability of a single dose of CTx-1301 50 mg trimodal tablets in healthy adult volunteers.
Fasted Arm: Following an overnight fast of at least 10.5 hours prior to dosing, subjectsshould be administered CTx-1301 (50 mg) with approximately240 mL (8 fluidounces) of water. No food should be allowed for at least 4 hours post-dose.Water can be allowed as desired except for at least one hour before and at least one hour after drug administration. Subjects should receive standardized meals as defined in the study schedule for the fasted treatment arm.
Fed Arm: Following an overnight fast of at least 10.5 hours prior to dosing, subjects should begin consuming the test meal 30 minutes prior to administration ofCTx-1301. CTx-1301 (50 mg) should be administered 30 minutes after thestart of the meal. CTx-1301 (50 mg) should be administered with approximately240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for at leastone hour before and at least one hour after drug administration. Subjects will receive the high-fat meal as described below for the fed treatment arm and standardized meals for all other meals.
A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (800 to 1000 calories) meal is used as the test meal for food-effect bioavailability (BA) and fed bioequivalence (BE) studies. This test meal allows 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. The test meal must be entirely consumed within 30 minutes prior to administration of CTx-1301; the test meal consists of two eggs fried in butter, two strips of bacon, two slices of toast with butter, four ounces of hash brown potatoes and eight ounces of whole milk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Gender
a. Male or Female
Age
<!-- -->
4. Compliance
Female subjects must agree not to donate eggs during the study and for 30 days following the last administration of study drug.
5. Consent
a. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written (signed and dated) obtained before any study-related activities are performed.
6. General Health
Subject has sufficient venous access at the time of screening to allow cannulation and/or venipuncture to obtain the required volume of blood for this study.
7. Smoking/Caffeine/Alcohol
<!-- -->
Subject must be able to refrain from using alcohol 48 hrs. prior to admission on Qualification day, check-in at Day -1 and for the duration of the stay at the study center until EOS.
8. Medications
a. Subject must be willing and able to take stimulant medications during participation in this trial.
9. Qualification
a. Subject satisfactorily completes the Qualification day, is able to safely tolerate 30 mg Focalin™ XR, and general behavior suggests that the subject could successfully complete the study in the opinion of an investigator.
Exclusion Criteria:
Medical History
Any history including but not limited to arterial hypertension, pulmonary arterial hypertension, myocardial infarction, peripheral vascular disease, stroke, or evidence of other cardiovascular disease or disorder, including but not limited to abnormalities such as:
Medications a. Subject has taken any medication that, in the opinion of an Investigator, has been shown to alter the PK of d-MPH.
b. Use of any prescription medication within 14 days prior to Qualification and Day -1 and/or use of any OTC medications (such as antacids, vitamins, minerals, dietary/herbal preparations, and nutritional supplements) within 7 days prior to Qualification and Day -1, unless jointly approved by an Investigator and Sponsor. Subjects may not use these medications for the full duration of the stay at the study center until EOS.
i. Subjects are permitted to take hormonal and hormone replacement therapy at acceptable levels if stable at least 30 days prior to Qualification, through the duration of the study, and for 30 days after the study ends.
ii. Acetaminophen (up to 2 grams per day) may be used during the study under the direction of the Investigator.
iii. COVID vaccine is allowed if taken at least 45 days prior to Qualification Protocol CTx-1301-013 Version 1.0 Page 25 of 49 CONFIDENTIAL iv. On a case-by-case basis, an Investigator is permitted to allow the use of certain concomitant medications, for example, to treat an AE, as long as an Investigator determines that the medication will not affect the subject's safety or study integrity (e.g., topical medications).
Alcohol/Substance Abuse
a. Lifetime history of alcohol or other substance abuse. b. Subject has positive urine alcohol test or urine screen for drugs of abuse at screening, qualification or check-in. (Screening visit urine MPH screen results are not required prior to Qualification day but are necessary prior to randomization on Day -1. Day-1 urine MPH screen results are not required prior to dosing in each Period).
Smoking
a. Subject is a current smoker or has recently discontinued smoking (i.e., regular use of any nicotinecontaining products within 3 months of screening). Occasional, social use, or routine environmental exposure to nicotine is acceptable.
Allergy/Intolerance
a. Subject has a history of allergy to d-MPH, to any component of the dosage form, or any other allergy, which, in the opinion of an Investigator, contraindicates their participation.
Clinical Studies
a. Receipt of an drug within the 30 days before screening day. b. Previous participation in a CTx-1301 study.
Personnel
a. An employee of the sponsor, study site, or members of their immediate family.
Blood
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive CTx-1301 in a fasted state
Drug: Dexmethylphenidate
Subjects will receive CTx-1301 in a fed state (high fat test meal)
Drug: Dexmethylphenidate
Subjects will be randomized to one of two sequences. Subjects will be dosed with 50 mg dose of Cox-1301 during each sequence. Subjects will serve as their own control.
Pharmacokinetic parameter (Cmax)
Maximum Concentration
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter (AUC0-inf)
Area Under the Curve from time 0 to infinity
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter (AUC0-last)
Area Under the Curve from time 0 to 28 hrs
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter K
Terminal Elimination Constant
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter T 1/2
Half Life
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter T max
Time of Maximum Concentration
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter T lag
Lag time
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter Cl/F
Apparent Clearance
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter Vd/F
Apparent Volume of Distribution
Time frame: Hour 0 to hour 28
Partial AUC
Area Under the Curve
Time frame: 0-3 hrs
Partial AUC
Area Under the Curve
Time frame: 3-6 hrs
Partial AUC
Area Under the Curve
Time frame: 3-7 hrs
Partial AUC
Area Under the Curve
Time frame: 6-9 hrs
Partial AUC
Area Under the Curve
Time frame: 7-12 hrs
Partial AUC
Area Under the Curve
Time frame: 9-12 hrs
Partial AUC
Area Under the Curve
Time frame: 12-16 hrs
Safety - ECG
Evaluation of changes in ECG measurements; heart rate, PR interval, RR interval, QT interval, QTc with Bazett correction, QTc with Fredericia correction intervals, and QRS duration.
Time frame: Day -1 to Day 4
Safety - Vital Signs
Evaluation of changes in Vital Sign measurements to include blood pressure (mmhg).
Time frame: Day -1 to Day 4
Safety - Vital Signs
Evaluation of changes in Vital Sign measurements to include weight (kg).
Time frame: Day -1 to Day 4
Safety - Vital Signs
Evaluation of changes in Vital Sign measurements to include heart rate (bpm).
Time frame: Day -1 to Day 4
Safety - Vital Signs
Evaluation of changes in Vital Sign measurements to include height (cm).
Time frame: Day -1 to Day 4
Safety - Vital Signs
Evaluation of Vital Sign measurements to include weight and height combined to report BMI in kg/m\^2.
Time frame: Day -1 to Day 4
Safety - Safety Labs
Evaluation of changes in Safety Lab measurements to include hematology, biochemistry, thyroid, serology, urinalysis, and drugs of abuse.
Time frame: Day -1 to Day 4
Safety - Physical Exam
Evaluation of changes in the Physical Exam to include general appearance, skin, head, eyes, ears, nose, throat, neck, spine, psychiatric, respiratory, cardiovascular, gastrointestinal, musculoskeletal, central nervous system, lymphatic, endocrine.
Time frame: Day -1 to Day 4
Safety - C-SSRS
C-SSRS is a tool designed to access and track suicidal adverse events (suicidal behavior and suicidal ideation).
Time frame: Day -1 to Day 4
Safety - Treatment Emergent Adverse Events (TEAEs)
Evaluation of Treatment Emergent Adverse Events (TEAEs)
Time frame: Day -1 to Day 4
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Dec 2024, 1 month.
Of 18 phase 1 interventional studies under Fasting, half reached primary completion within 1 month of starting (the median), counting those still running; a quarter within 0 and three quarters within 3. This study's 1 month is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmethylphenidate
Cingulate Therapeutics